JACINTA CRUZ: Open Payments
NPI 1588908628 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$779 in 38 payments from 15 companies in 2025. Trend: 2023 $359 · 2024 $893 · 2025 $779
Food & beverage: $779
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $187 |
| ABBVIE INC. | 9 | $171 |
| Vanda Pharmaceuticals Inc. | 5 | $100 |
| Neurocrine BioSciences, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $26 |
| ACADIA Pharmaceuticals Inc | 1 | $24 |
| EMD Serono, Inc. | 1 | $24 |
Products named: REXULTI, VRAYLAR, FANAPT, INGREZZA, TRINTELLIX, Auvelity, AUSTEDO XR, ZURZUVAE.
Industry payments across NV — which companies pay providers there.
